Company: DVAX
Filing Date: 2025-06-04
Form Type: DEFA14A
Source: 0001193125-25-135000
Chunk: 0

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-06-04
Form: DEFA14A
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box:

| ☐ | Preliminary Proxy Statement |

| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 
 14a-6(e)(2))                                                       |

| ☐ | Definitive Proxy Statement |

| ☒ | Definitive Additional Materials |

| ☐ | Soliciting Material Pursuant to §240.14a-12 |

Dynavax Technologies Corporation (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check the appropriate box):

| ☒ | No fee required. |

| ☐ | Fee paid previously with preliminary materials. |

| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rule 
 14a-6(i)(1) and 0-11.                                                         |

This Schedule 14A filing consists of the following press release distributed by Dynavax Technologies Corporation (the “Company”) to its stockholders in connection with the Company’s 2025 Annual Meeting of Stockholders. The press release was first used or made available on June 4, 2025. Dynavax Comments on Glass Lewis Recommendation Dynavax is Already Delivering Significant Long Term Stockholder Value Through Execution of Current Strategy Overseen by Board; Deep Track’s Inferior Short-Term Plan and Nominees are Not in the Best Interests of All Stockholders Glass Lewis’ Recommendation Recognizes the Significant Stockholder Value Creation and Differentiated Capital Return Overseen by the Dynavax Board Reiterates ISS and Egan Jones Recommendations that Stockholders Support ALL Dynavax Nominees and Deep Track Board Representation is Not Warranted Urges Stockholders to Vote “FOR” ALL Four of Dynavax’s Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., June 4, 2025 — Dynavax Technologies Corporation (Nasdaq: DVAX) (“Dynavax” or the “Company”), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today commented on a report published by Glass, Lewis & Co. (“Glass Lewis”)